Explore our strategy and projects
to learn about the future of our company
Results FY 2023 (€/MLN)
1,148
Revenues
375
Adjusted EBITDA
224
Adjusted net profit
209
Free cash flow
Stock price
Discover morePress releases
15/03/24 - 13:35
Price sensitiveThe Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share
LIAISON PLEX® System: the new multiplexing platform of the Group
Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.
Keep
in touch
Sign up for our investor alerts
and stay informed
on the latest developments